



ISOGENICA LAUNCHES A NEW LIBRARY BOOSTING OUTPUTS FOR VHH ANTIBODY DISCOVERY

Introducing **VHHantage^(TM)** allowing maximised diversity humanised VHH binders with significantly reduced liabilities, allowing the efficient discovery developable antibodies.

The VHHantage^(TM) library ensures standardised flanking sequences that can be easily slotted into our bi- and tri-specific plug-and-play platform, reaching proof-of-concept faster.


[LEARN MORE ABOUT OUR VHH LIBRARIES](#)

VHH MULTI-SPECIFICS PLUG-&-PLAY PLATFORM

Large VHH Libraries generate binders to diverse epitopes



Expression cassettes



Bi-/tri-specific candidates



Efficient generation of bi- and tri-specific VHH next-generation biotherapeutics supported by a pipeline of developable VHHs. Isogenica have developed fully synthetic, *in vitro* plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific VHH and have exemplified this in *in vitro* studies.

[KICK START YOUR MULTI-SPECIFICS PROJECT](#)



Isogenica are collaborating with Phenotypeca, a biofoundry business who create and own yeast synthetic biology solutions to make any recombinant protein, including biologic drugs. Read the full [Press Release](#) and find out how this collaboration advances our discovery efforts.

Isogenica have a diverse array of collaborations, reflecting the how we are developing maximum potential for VHH therapeutics. Our collaborations span clinical applications, machine learning and making our discovery and development more efficient

[VIEW OUR COLLABORATORS](#)



Copyright © Isogenica 2022 All rights reserved.



Want to change how you receive these emails?
You can [update your preferences](#) or [unsubscribe from this list](#).

